Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of RAS: proven and potential vulnerabilities.

Biochemical Society transactions - 30 Oct 2020

Zuberi Mariyam, Khan Imran, O'Bryan John P

Abstract excerpt

RAS is a membrane localized small GTPase frequently mutated in human cancer. As such, RAS has been a focal target for developing cancer therapeutics since its discovery nearly four decades ago. However, efforts to directly target RAS have been challenging due to the apparent lack of readily discernable deep pockets for binding small molecule inhibitors leading many to consider RAS as undruggable. An important...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Allosteric Site
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Metabolism

Share to Molecular Conformation

Share to Neoplasm Transplantation

Share to Piperazines

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 32869838
DOI: 10.1042/BST20190023
PMCID: PMC7875515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of RAS: proven and potential vulnerabilities.PMID 32869838Read ↗

Therapeutic targeting of RAS: New hope for drugging the "undruggable".Semantic proximity Read ↗

Drugging the Undruggable: Advances on RAS Targeting in Cancer.Semantic proximity Read ↗

KRAS: From undruggable to a druggable Cancer Target.Semantic proximity Read ↗

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.Semantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

Progress on Covalent Inhibition of KRAS(G12C).Semantic proximity Read ↗

RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.Semantic proximity Read ↗

Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.Semantic proximity Read ↗

Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.Semantic proximity Read ↗

Improving Prospects for Targeting RAS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.